Related Experiment Videos
P53: an ubiquitous target of anticancer drugs
1Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA. mikhailb@box-m.nih.gov
Abstract:
The p53 tumor suppressor can induce growth arrest, apoptosis and cell senescence. Not surprisingly, p53 is an appealing target for therapeutic intervention. Although current anticancer agents do not directly interact with p53, these agents (including DNA damaging drugs, antimetabolites, microtubule-active drugs and inhibitors of the proteasome) cause accumulation of wt p53. Depending on the p53 status of cancer cells, diverse therapeutic strategies are under development. These include pharmacological rescue of mutant p53 function and reactivation of wt p53 in E6-expressing cells. For protection of normal cells, strategies range from abrogation of wt p53 induction, thereby decreasing the toxicity of DNA damaging agents, to activation of wt p53-dependent checkpoints, thereby protecting cells against cell cycle-dependent therapeutics.
Insights
The p53 tumor suppressor protein plays a key role in cancer by inducing growth arrest and apoptosis. Therapeutic strategies targeting p53 are being developed, focusing on both wild-type (wt) p53 and mutant p53, to enhance cancer treatment and protect normal cells.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- The p53 tumor suppressor protein is a critical regulator of cellular responses to stress, including growth arrest, apoptosis, and senescence.
- p53 is a highly sought-after target for cancer therapy due to its pivotal role in preventing tumor formation and progression.
- Current chemotherapies, while not directly targeting p53, lead to the accumulation of wild-type (wt) p53, influencing treatment outcomes.
Purpose of the Study:
- To explore diverse therapeutic strategies for cancer treatment that leverage the p53 pathway.
- To investigate methods for targeting both wild-type (wt) p53 and mutant p53 in cancer cells.
- To develop strategies for protecting normal cells from the toxic effects of cancer therapeutics by modulating p53 activity.
Main Methods:
- Review of existing and emerging therapeutic strategies involving the p53 pathway.
- Analysis of approaches for rescuing mutant p53 function.
- Examination of methods for reactivating wt p53 in specific cellular contexts (e.g., E6-expressing cells).
- Evaluation of strategies for abrogating wt p53 induction to reduce drug toxicity.
- Assessment of wt p53-dependent checkpoint activation for cellular protection.
Main Results:
- Diverse therapeutic strategies targeting p53 are under development, tailored to the specific p53 status of cancer cells.
- Approaches include restoring function to mutant p53 and reactivating wt p53 in E6-expressing cells.
- Strategies for normal cell protection involve modulating wt p53 induction or activating p53-dependent checkpoints.
Conclusions:
- The p53 pathway presents a versatile target for developing novel anticancer therapies.
- Tailoring therapeutic interventions based on p53 status (wild-type or mutant) is crucial for efficacy.
- Modulating p53 activity offers potential for both enhancing anti-cancer effects and mitigating treatment-related toxicity in normal tissues.